International Stem Cell Corporation to Expand its Revenue-Generating Biomedical Businesses to Support Ongoing & Future Clinical Trials
International Stem Cell Corporation recently announced that ISCO’s wholly owned subsidiaries Lifeline Cell Technology (LCT) and Lifeline Skin Care (LSC) expanded their manufacturing operations, OEM business, and product lines.
“ISCO was one of the first stem cell biotech companies to build a business model in which revenue-generating subsidiaries operate under a parent R&D company. This not only decreases cash burn while conducting our Parkinson’s disease clinical trial, but gives us more confidence in ISCO’s future,” commented Russell Kern, PhD, Executive VP and Chief Scientific Officer of ISCO.
Lifeline Cell Technology LLC, a research products business that develops, manufactures, and commercializes human cell culture products, expanded and improved its media manufacturing operation by doubling the size of clean rooms, as well as the cell culture media production capacity. LCT has expanded its catalog by launching cardiac fibroblasts and skeletal muscle cell culture system, which includes differentiation media. Also, while working on bringing more international distributors, LCT expanded its domestic sales force together with OEM business. In their catalog, LCT currently has 60 different cell types and 115 media products, which is comprised of 34 kits for growing the different cell types, 24 different cell culture media, and 57 growth factors/cytokines.
Lifeline Skin Care Inc., a leader in stem cell skin care anti-aging solutions, expanded its marketing operations and sales force, and will be launching a new product in October 2017, Intense Moisture Serum, a high-tech serum that combines advanced stem cell technology with powerful concentrations of moisturizers. The current consumer products line features 16 products, while the professional line features 12.
“Backed by years of intensive research and development, Lifeline Skin Care has developed a unique and advanced skin care line using cutting-edge technologies that improves the skin’s overall appearance. It is definitely one of my top Go To skin care lines,” commented Dr. Paul E. Chasan, MD, FACS.
International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of human pluripotent stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell.
Total Page Views: 946
